title: Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
abstract: BACKGROUND
  We determined health plan paid costs and healthcare resource usage of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
  
  
  METHODS
  CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database. We examined demographics, prevalence of comorbidities, prescribed drugs, place of service, and mean annual health plan paid costs per patient.
  
  
  RESULTS
  From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria. The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%). The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.
  
  
  CONCLUSIONS
  Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy usage. Studies are needed to determine optimal long-term treatment strategies for CIDP, particularly related to IVIg.
authors.affiliation: Department of Medicine - Neurology, Duke University Medical Center, DUMC Box 3403, Durham, North Carolina, 27710, USA.
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Guptill
authors.forename: Mark B
authors.initials: MB
authors.lastname: Bromberg
authors.forename: Li
authors.initials: L
authors.lastname: Zhu
authors.forename: Bal K
authors.initials: BK
authors.lastname: Sharma
authors.forename: Amy R
authors.initials: AR
authors.lastname: Thompson
authors.forename: Andrew
authors.initials: A
authors.lastname: Krueger
authors.forename: Donald B
authors.initials: DB
authors.lastname: Sanders
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000588:Amines / Q000191:economics / Q000627:therapeutic use; D000700:Analgesics / Q000191:economics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D015897:Comorbidity; D003365:Costs and Cost Analysis; D003509:Cyclohexanecarboxylic Acids / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D004576:Electromyography; D005260:Female; D000077206:Gabapentin; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use; D007348:Insurance, Health / Q000191:economics*; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction; D009460:Neurologic Examination; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology*; D011239:Prednisolone / Q000191:economics / Q000627:therapeutic use; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000191:economics / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D003509:Cyclohexanecarboxylic Acids; D016756:Immunoglobulins, Intravenous; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D011239:Prednisolone
keywords: CIDP; chronic inflammatory polyradiculoneuropathy; cost analysis; costs; health care cost; intravenous immune globulin